Chemical Compound Review:
ACMC-20n5y6 4-(2-aminopropoxy)-3,5- dimethyl-phenol
Synonyms:
AR-1F5825, AC1L3PW4, AC1Q564T, 150284-88-1, p-Hydroxymexiletine, ...
- Influence of the CYP2D6*10 allele on the metabolism of mexiletine by human liver microsomes. Senda, C., Yamaura, Y., Kobayashi, K., Fujii, H., Minami, H., Sasaki, Y., Igarashi, T., Chiba, K. British journal of clinical pharmacology. (2001)
- The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation. Broly, F., Vandamme, N., Libersa, C., Lhermitte, M. British journal of clinical pharmacology. (1991)
- Evaluation of mexiletine clearance in a Japanese population. Ueno, K., Tamamura, A., Matsumoto, K., Komamura, K., Kamakura, S., Miyatake, K., Shibakawa, M. The Annals of pharmacotherapy. (2002)
- Single-dose quinidine treatment inhibits mexiletine oxidation in extensive metabolizers of debrisoquine. Broly, F., Vandamme, N., Caron, J., Libersa, C., Lhermitte, M. Life Sci. (1991)
- Pharmacokinetics of mexiletine and its metabolites, hydroxymethylmexiletine and p-hydroxymexiletine, after single oral administration in healthy subjects. Paczkowski, D., Sadowski, Z., Filipek, M., Koliński, P. Polish journal of pharmacology and pharmacy. (1990)
- Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers. Otani, M., Fukuda, T., Naohara, M., Maune, H., Senda, C., Yamamoto, I., Azuma, J. Eur. J. Clin. Pharmacol. (2003)